The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases
- PMID: 34734369
- PMCID: PMC8926958
- DOI: 10.1007/s11605-021-05188-7
The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases
Abstract
Background: Hepatosteatosis is the earliest stage in the pathogenesis of nonalcoholic fatty (NAFLD) and alcoholic liver disease (ALD). As NAFLD is affecting 10-24% of the general population and approximately 70% of obese patients, it carries a large economic burden and is becoming a major reason for liver transplantation worldwide. ALD is a major cause of morbidity and mortality causing 50% of liver cirrhosis and 10% of liver cancer related death. Increasing evidence has accumulated that gut-derived factors play a crucial role in the development and progression of chronic liver diseases.
Methods: A selective literature search was conducted in Medline and PubMed, using the terms "nonalcoholic fatty liver disease," "alcoholic liver disease," "lipopolysaccharide," "gut barrier," and "microbiome."
Results: Gut dysbiosis and gut barrier dysfunction both contribute to chronic liver disease by abnormal regulation of the gut-liver axis. Thereby, gut-derived lipopolysaccharides (LPS) are a key factor in inducing the inflammatory response of liver tissue. The review further underlines that endotoxemia is observed in both NAFLD and ALD patients. LPS plays an important role in conducting liver damage through the LPS-TLR4 signaling pathway. Treatments targeting the gut microbiome and the gut barrier such as fecal microbiota transplantation (FMT), probiotics, prebiotics, synbiotics, and intestinal alkaline phosphatase (IAP) represent potential treatment modalities for NAFLD and ALD.
Conclusions: The gut-liver axis plays an important role in the development of liver disease. Treatments targeting the gut microbiome and the gut barrier have shown beneficial effects in attenuating liver inflammation and need to be further investigated.
Keywords: ALD; Gut barrier; LPS; Microbiome; NAFLD.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.Biomed Pharmacother. 2021 Mar;135:111235. doi: 10.1016/j.biopha.2021.111235. Epub 2021 Feb 6. Biomed Pharmacother. 2021. PMID: 33561650 Review.
-
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 9. doi: 10.1007/s00210-025-04069-z. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40202676 Review.
-
Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.Clin Biochem. 2015 Sep;48(13-14):923-30. doi: 10.1016/j.clinbiochem.2015.06.023. Epub 2015 Jul 4. Clin Biochem. 2015. PMID: 26151226 Free PMC article. Review.
-
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056. Biomolecules. 2021. PMID: 35053205 Free PMC article. Review.
-
Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.Sci Rep. 2017 Mar 28;7:45176. doi: 10.1038/srep45176. Sci Rep. 2017. PMID: 28349964 Free PMC article.
Cited by
-
Healthy diet intervention reverses the progression of NASH through gut microbiota modulation.Microbiol Spectr. 2024 Jan 11;12(1):e0186823. doi: 10.1128/spectrum.01868-23. Epub 2023 Nov 29. Microbiol Spectr. 2024. PMID: 38018983 Free PMC article.
-
Crucial role of T cells in NAFLD-related disease: A review and prospect.Front Endocrinol (Lausanne). 2022 Nov 15;13:1051076. doi: 10.3389/fendo.2022.1051076. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36457551 Free PMC article. Review.
-
BRISC is required for optimal activation of NF-κB in Kupffer cells induced by LPS and contributes to acute liver injury.Cell Death Dis. 2023 Nov 15;14(11):743. doi: 10.1038/s41419-023-06268-z. Cell Death Dis. 2023. PMID: 37968261 Free PMC article.
-
Soy Protein Concentrate Diets Inversely Affect LPS-Binding Protein Expression in Colon and Liver, Reduce Liver Inflammation, and Increase Fecal LPS Excretion in Obese Zucker Rats.Nutrients. 2024 Mar 28;16(7):982. doi: 10.3390/nu16070982. Nutrients. 2024. PMID: 38613016 Free PMC article.
-
Therapeutic targeting of obesity-induced neuroinflammation and neurodegeneration.Front Endocrinol (Lausanne). 2025 Jan 17;15:1456948. doi: 10.3389/fendo.2024.1456948. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39897964 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials